What changed in this filing

/stocks — the workspaceLOADING

Item 9A. Controls and Procedures

2023-03-22 compared with 2022-03-24 · 142 added, 266 removed, 856 unchanged (32% of the section changed)

41 unchanged sentences

  All schedules are omitted because they are inapplicable or not required or the required information is shown in the financial statements or notes thereto.

EXHIBIT INDEX

Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc.

15 unchanged sentences

Form of Placement Agent Warrant Agreement issued in February 2020 offering (incorporated by reference to Exhibit 4.2 of the Form 8-K filed February 6, 2020)

Description of Registrant's Securities 

Description of Registrant's Securities (incorporated by reference to Exhibit 4.10 of the Form 10-K filed March 24, 2022)

Moleculin Biotech, Inc.

9 unchanged sentences

1 to the Patent and Technology License Agreement dated April 2, 2012 by and between The Board of Regents of the University of Texas System and IntertechBio Corporation (incorporated by reference to exhibit 10.6 of the Form S-1/A filed March 21, 2016)

Patent and Technology Development and License Agreement June 28, 2012 by and between Annamed, Inc.

and Dermin Sp.

z.o.o (incorporated by reference to exhibit 10.7 of the Form S-1/A filed April 15, 2016)

Patent and Technology Development and License Agreement dated April 15, 2011 by and between IntertechBio Corporation and Dermin Sp.

z.o.o (incorporated by reference to exhibit 10.8 of the Form S-1/A filed March 21, 2016)

Patent and Technology Development and License Agreement dated October 27, 2010 by and between Moleculin, LLC and Dermin Sp.

z.o.o (incorporated by reference to exhibit 10.9 of the Form S-1/A filed March 21, 2016)

Rights Transfer Agreement dated between Moleculin Biotech, Inc.

5 unchanged sentences

(incorporated by reference to exhibit 10.13 of the Form S-1/A filed April 15, 2016)

10.10 **

Employment Agreement between Moleculin Biotech, Inc.

1 unchanged sentence

Foster dated August 19, 2016 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed August 25, 2016)

10.11 **

Executive Employment Agreement between Moleculin Biotech, Inc.

and Walter Klemp dated October 13, 2016 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed October 13, 2016)

Development Collaboration Agreement between Moleculin Biotech, Inc.

and Dermin Sp.

dated September 30, 2016 (incorporated by reference to Exhibit 10.4 of the Form 10-Q filed November 21, 2016)

Lease Agreement for 5300 Memorial (incorporated by reference to Exhibit 10.1 of the Form 10-Q filed May 14, 2018)

3 unchanged sentences

(incorporated by reference to Exhibit 10.2 of the Form 10-Q filed May 14, 2018)

Sublicense Agreement dated as of February 19, 2019 entered into between the Company and WPD Pharmaceuticals.

(incorporated by reference to Exhibit 10.21 of the Form 10-K filed February 21, 2019)

Sublicense Agreement dated as of February 19, 2019 entered into between the Company and Animal Life Sciences, LLC (incorporated by reference to Exhibit 10.22 of the Form 10-K filed February 21, 2019) 

4 unchanged sentences

Scientific Advisory Board Agreement, dated February 28, 2020, entered into between the Company and Waldemar Priebe, PhD (incorporated by reference to Exhibit 10.26 of the Form 10-K filed March 19, 2020)   

Amended and Restated Sublicense Agreement entered into between the Company and WPD Pharmaceuticals dated December 20, 2021 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed December 27, 2021)

Assignment Consent Letter by and between WPD Pharmaceuticals Sp.

z o.o and LPC Enterprises, LLC and Moleculin Biotech, Inc.

(incorporated by reference to Exhibit 10.2 of the Form 8-K filed December 27, 2021)

At Market Issuance Sales Agreement, dated June 25, 2021, by and among the Company and Oppenheimer & Co.

(incorporated by reference to Exhibit 1.1 of the Form 8-K filed June 25, 2021)

Purchase Agreement dated June 25, 2021 by and between Moleculin Biotech, Inc.

11 unchanged sentences

Patent And Technology License Agreement dated June 29, 2017 by and between The Board of Regents of The University Of Texas System on behalf of The University Of Texas M.